Is hCG FDA-approved, and what does the research show?

What is hCG?

Human chorionic gonadotropin is a hormone the placenta makes during pregnancy, and it appears in the urine of pregnant women ³, ². Pregnyl's label describes it as a polypeptide hormone of two chains, an alpha and a beta subunit ². The alpha chain is essentially identical to that of the pituitary hormones luteinizing hormone (LH), follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH), and the beta chains differ ². Pregnyl is a purified preparation obtained from that urine ². A second form, made by recombinant technology rather than extracted from urine, is approved too, under the name choriogonadotropin alfa ¹, ⁶.

Is hCG FDA-approved?

Yes, for three uses, and only as a prescription injection ³, ². Pregnyl's label lists three indications ². The first is prepubertal cryptorchidism not due to anatomical obstruction, an undescended testicle in a boy before puberty ². The second is selected cases of hypogonadotropic hypogonadism in males, which the label defines as hypogonadism secondary to a pituitary deficiency ². The third is induction of ovulation and pregnancy in an infertile woman who does not ovulate, has no primary ovarian failure, and has been treated with human gonadotropins ².

FDA's Drugs@FDA lists four hCG applications with a product in prescription marketing status, data updated November 6, 2026 ⁶. They are Pregnyl (Organon, first approved October 20, 1976), Novarel (Ferring, January 15, 1974), and an unbranded chorionic gonadotropin (Fresenius Kabi, March 5, 1973) ⁶. The fourth is Ovidrel, the recombinant choriogonadotropin alfa (EMD Serono, September 20, 2000) ⁶. Each was approved as a drug, and each former new drug application was deemed a biologics license application on March 23, 2020 ⁶. Several older hCG applications and strengths are listed as discontinued ⁶.

hCG is not approved for weight loss ³, ². FDA's page on hCG products for weight loss states: "There are no FDA-approved HCG products for weight loss" ³. It adds that "FDA has not approved prescription HCG for any other uses, including weight loss" ³. The Pregnyl label carries the same position at the head of its indications, stating that hCG "has not been demonstrated to be effective adjunctive therapy in the treatment of obesity" ².

The over-the-counter hCG drops, pellets and sprays sold as "homeopathic" for weight loss are a different matter ³. FDA and the Federal Trade Commission sent seven joint warning letters to firms selling them, for "selling unapproved new drugs and misbranded drugs that make unsubstantiated claims about weight loss" ³. FDA's page states that "all drug products claiming to include 'homeopathic' HCG are illegally marketed" and that FDA "has not evaluated these products for safety or effectiveness" ³. FDA advises consumers using them for weight loss to stop, to stop following any labeled dieting instructions, and to discard the product ³. The page's content is dated May 4, 2016 ³.

The route to hCG is a prescription from a licensed clinician, dispensed as the approved product ³, ². FDA notes that approved products are sometimes used off-label, and that off-label use "usually presents greater uncertainty about both the risks and benefits" ³.

See the FDA status of every peptide, updated weekly.

How does hCG work?

hCG acts almost identically to LH, with a small degree of FSH activity as well, as the label describes it ². In men it stimulates the Leydig cells of the testis to make androgens, the male sex hormones that include testosterone ². In women it can stand in for the mid-cycle LH surge that triggers ovulation, and in pregnancy it keeps the corpus luteum producing progesterone ². In a boy with an undescended testicle, the androgen stimulation may bring the testicle down where nothing blocks the descent, and the descent is usually reversible when hCG stops ².

These mechanisms stand behind the approved uses, and they are the FDA-approved label's account rather than a hypothesis ². On weight, the label states that hCG "has no known effect on fat mobilization, appetite or sense of hunger, or body fat distribution" ².

What does the research show?

The evidence divides into the approved uses, which rest on the FDA-approved label, and two uses people search for, weight loss and testosterone support ³, ². The approved uses carry the label's weight; the searched uses carry only the trials and reviews that have tested them ⁴, ⁵, ⁷.

Studied in people for fertility: a Cochrane review, online April 23, 2016, pooled 18 randomized trials with 2,952 subfertile women having IVF or ICSI ¹. Fifteen trials compared recombinant hCG with urinary hCG as the trigger for final egg maturation, and three compared recombinant luteinizing hormone with urinary hCG ¹. It found no conclusive evidence of a difference in ongoing pregnancy or live birth between the two forms ¹. The odds ratio was 1.15, with a 95 percent confidence interval from 0.89 to 1.49, across 7 trials and 1,136 women, evidence the authors graded as moderate quality ¹. Rates of ovarian hyperstimulation syndrome, a serious complication of fertility drugs, showed no evidence of a difference either, on low-quality evidence ¹.

Recombinant hCG had fewer other adverse events, mostly injection-site reactions, in one analysis, but the difference disappeared when the authors allowed for the variation between trials ¹. The review compared recombinant products with urinary hCG, not hCG against no trigger, so it does not test whether hCG itself raises pregnancy rates ¹.

Studied in people for testosterone: a randomized trial, online June 14, 2018, enrolled 282 men with hypogonadism who wished to preserve their fertility ⁵. They were assigned to clomiphene citrate (95 men), hCG injections (94), or both (94), and testosterone was measured at baseline, one month and three months ⁵. Testosterone rose in all three groups at both time points ⁵. Across the groups the mean went from 2.31 nmol/L at baseline to 5.17 nmol/L at three months, with no significant difference between them ⁵.

Symptom scores on a hypogonadism questionnaire improved in all three groups, and the combination improved them more than either drug alone ⁵. The trial ran three months, and its abstract reports neither fertility outcomes nor adverse events ⁵.

A review of non-testosterone treatments, online April 29, 2021, pooled five hCG studies with 196 men of mean age 41.7 ⁴. Mean total testosterone was 284.5 ng/dL before treatment and 565.6 ng/dL after, pooled before-and-after figures rather than a comparison against placebo ⁴. The authors conclude that non-testosterone therapies are efficacious in hypogonadal men, and call for studies of their effect on erectile function ⁴.

For weight loss, the evidence runs the other way ³, ², ⁷. A meta-analysis in the British Journal of Clinical Pharmacology, September 1995, scored eight controlled and 16 uncontrolled trials of hCG as an adjunct in treating obesity ⁷. Most scored poorly on method, and of the 12 better-scoring studies, all of them controlled, one reported hCG a useful adjunct ⁷. The authors concluded that there is "no scientific evidence that HCG is effective in the treatment of obesity" ⁷. In their words it brings about neither weight loss nor fat redistribution, and it neither reduces hunger nor induces a feeling of well-being ⁷.

FDA's position is that "current scientific evidence does not support the claim that HCG is safe and effective for weight loss or for the treatment of obesity" ³. The label says the same in its own words ². There is no substantial evidence that hCG increases weight loss "beyond that resulting from caloric restriction", nor that it changes fat distribution or eases the hunger of a calorie-restricted diet ².

No controlled trial of hCG for weight loss published after 1995 is among this page's sources, and no trial of hCG for cryptorchidism is either ², ⁷. For cryptorchidism the label states that descent after hCG is permanent in some cases and temporary in most ².

What are the side effects?

The Pregnyl label lists, for both sexes, hypersensitivity reactions including anaphylaxis, which it says "has been reported with urinary-derived hCG products" ². It also lists irritability, restlessness, depression, headache, edema, fatigue, and bruising, pain, redness, swelling or itching at the injection site ².

In women, the main warning is ovarian hyperstimulation syndrome, OHSS, a rapid leak of fluid into the abdomen and chest ². The label says "Severe OHSS may be life-threatening" ². The label also warns of thromboembolism, pulmonary embolism, stroke and, in rare cases, death reported with gonadotropin therapy in women, with or without OHSS ². Multiple births, ovarian torsion, ectopic pregnancy and a raised rate of miscarriage are listed for women having fertility treatment, the miscarriage link not established as causal ².

In men, the label lists water and sodium retention after high dosages, occasional gynecomastia, and, in boys treated for cryptorchidism, precocious puberty, at which treatment is stopped ². It advises caution in patients with heart or kidney disease, high blood pressure, epilepsy, migraine or asthma, and states that androgen secretion induced by hCG may cause fluid retention ².

FDA has received reports of serious adverse events with hCG injections used for weight loss, "including cases of pulmonary embolism, depression, cerebrovascular issues, cardiac arrest, and death" ³. FDA also notes that the very low calorie diets paired with "homeopathic" hCG products raise the risk of gallstones, electrolyte imbalance and heart arrhythmias ³.

The label's contraindications are prior hypersensitivity to human gonadotropins, high FSH indicating primary gonadal failure in women, and uncontrolled thyroid, adrenal or pituitary disorders ². They also include tumors of the hypothalamus or pituitary, and tumors of the ovary, breast or uterus in females or of the breast or prostate in males ². Malformations of the reproductive organs or uterine fibroids incompatible with pregnancy, and abnormal vaginal bleeding of undetermined origin, complete the list ².

In sport

WADA, the World Anti-Doping Agency, names chorionic gonadotrophin (CG) on its 2026 Prohibited List under S2.2.1, "Testosterone-stimulating peptides in males", prohibited at all times, in and out of competition ⁸. That heading reads "in males", and chorionic gonadotrophin appears nowhere else on the list ⁸.

What JumpstartMD offers

JumpstartMD does not prescribe hCG. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 9, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.